“That is fanciful thinking and fun to contemplate but not very likely in the big scheme of biotech. Hey, go for it if that floats your boat. I will not harbor unrealistic expectations, and I have very high expectations here.”

I was simply pointing pointing out your flawed statement regarding the market valuation of biotechs/BPs. I was not agreeing with very high PPS or market predictions.

Breast cancer alone would likely bring multiple billions each year and even more if leronlimab is proved to work in multiple cancers. But like you pointed out in your first post, cancer revenues could be a year or more away. I’d hope that the basket trial demonstrates phenomenal results and the FDA approveS a phase 4, but like yourself, I have high expectations but understand that sometimes it takes years for drug indications to pan out and bring in revenues.